James C. Shanks

688 total citations · 1 hit paper
22 papers, 423 citations indexed

About

James C. Shanks is a scholar working on Neurology, Oncology and Epidemiology. According to data from OpenAlex, James C. Shanks has authored 22 papers receiving a total of 423 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Neurology, 4 papers in Oncology and 4 papers in Epidemiology. Recurrent topics in James C. Shanks's work include Neuroendocrine Tumor Research Advances (4 papers), Cleft Lip and Palate Research (4 papers) and Voice and Speech Disorders (4 papers). James C. Shanks is often cited by papers focused on Neuroendocrine Tumor Research Advances (4 papers), Cleft Lip and Palate Research (4 papers) and Voice and Speech Disorders (4 papers). James C. Shanks collaborates with scholars based in United States and Sweden. James C. Shanks's co-authors include Paul J. Catalano, Matthew H. Kulke, James C. Yao, Andrew Hendifar, Manisha H. Shah, George A. Fisher, Mark M. Zalupski, Carlos J. Suarez, Peter J. O’Dwyer and Diane Reidy‐Lagunes and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

James C. Shanks

19 papers receiving 409 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)

2022 125 citations Pamela L. Kunz, Noah Graham et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by James C. Shanks

Since Specialization

Citations

This map shows the geographic impact of James C. Shanks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James C. Shanks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James C. Shanks more than expected).

Fields of papers citing papers by James C. Shanks

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James C. Shanks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James C. Shanks. The network helps show where James C. Shanks may publish in the future.

Co-authorship network of co-authors of James C. Shanks

This figure shows the co-authorship network connecting the top 25 collaborators of James C. Shanks. A scholar is included among the top collaborators of James C. Shanks based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James C. Shanks. James C. Shanks is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211) breakdown → 2022 ·Journal of Clinical Oncology ·Pamela L. Kunz, Noah Graham, Paul J. Catalano, Halla Nimeiri, George A. Fisher, Teri A. Longacre, Carlos J. Suarez, Brock A. Martin, James C. Yao, Matthew H. Kulke, Andrew Hendifar, James C. Shanks, Manisha H. Shah, Mark M. Zalupski, (unknown), Diane Reidy‐Lagunes, Jonathan Strosberg, Peter J. O’Dwyer, Al B. Benson	125
2	A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT (ECOG-ACRIN E2211). 2022 ·Journal of Clinical Oncology ·Pamela L. Kunz, Noah Graham, Paul J. Catalano, Halla Nimeiri, George A. Fisher, Teri A. Longacre, Carlos J. Suarez, Daniel B. Rubin, James C. Yao, Matthew H. Kulke, Andrew Hendifar, James C. Shanks, Manisha H. Shah, Mark M. Zalupski, (unknown), Diane Reidy‐Lagunes, Jonathan Strosberg, Terence Z. Wong, Peter J. O’Dwyer, Al B. Benson	13
3	Aqueductal CSF Stroke Volume Is Increased in Patients with Idiopathic Normal Pressure Hydrocephalus and Decreases after Shunt Surgery 2019 ·American Journal of Neuroradiology ·James C. Shanks, Karin Markenroth Bloch, Katarina Laurell, Kristina Giuliana Cesarini, Markus Fahlström, Elna‐Marie Larsson, Johan Virhammar	25
4	A Randomized Phase II Study to Determine the Effect of 2 Different Doses of Aflibercept in Patients With Metastatic Renal Cell Carcinoma (ECOG-ACRIN [E4805]) 2017 ·Clinical Genitourinary Cancer ·Роберто Пили, Opeyemi A. Jegede, Michael A. Carducci, Judith Manola, (unknown), (unknown), Glenn Liu, James C. Shanks, Shaker R. Dakhil, Janice P. Dutcher, Robert S. DiPaola	3
5	Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive‐stage small cell lung cancer: A trial of the ECOG‐ACRIN Cancer Research Group (E1508) 2016 ·Cancer ·Chandra P. Belani, Suzanne E. Dahlberg, Charles M. Rudin, Martin Fleisher, Helen X. Chen, Naoko Takebe, Mario R. Velasco, William Tester, Keren Sturtz, Christine L. Hann, James C. Shanks, Manish Monga, Suresh S. Ramalingam, Joan H. Schiller	61
6	Occurrences of opportunistic infections in chronic myelogenous leukemia patients treated with imatinib mesylate 2010 ·Leukemia Research ·(unknown), James C. Shanks, Howard R. Terebelo	5
7	Dual Proteasome and mTOR Inhibition Promotes Apoptosis in Non-Hodgkin Lymphoma Cell Lines 2008 ·Blood ·James C. Shanks, (unknown), Catherine Lobocki, Howard R. Terebelo	2
8	A history of teaching speech after laryngectomy by lay instructors 2001 ·Current Opinion in Otolaryngology & Head & Neck Surgery ·James C. Shanks	0
9	Use of Web-based Technology in a Peer-teaching Program 2000 ·Academic Medicine ·James C. Shanks, (unknown), Ilene Harris	3
10	Coping with Laryngeal Cancer 1995 ·Seminars in Speech and Language ·James C. Shanks	3
11	Velopharyngeal incompetence manifested initially in playing a musical instrument 1990 ·Journal of Voice ·James C. Shanks	5
12	A functional speech impression used to fabricate a maxillary speech prosthesis for a partial glossectomy patient 1984 ·Journal of Prosthetic Dentistry ·Jonathan C. Knowles, Varoujan A. Chalian, James C. Shanks	14
13	Effect of Gastroesophageal Reflux on Esophageal Speech 1983 ·Journal of Clinical Gastroenterology ·(unknown), Glen A. Lehman, James C. Shanks, Eric Blom, Rocco L. Brunelle	7
14	A Response to Glaser et al 1979 ·Journal of Speech and Hearing Disorders ·(unknown), James C. Shanks	0
15	Velopharyngeal Relationships of /i/ and /s/ as Seen Cephalometrically for Persons with Suspected Incompetence 1978 ·Journal of Speech and Hearing Disorders ·(unknown), James C. Shanks	3
16	The Relationship between Esophageal Speech Proficiency and Selected Measures of Auditory Function 1974 ·Journal of Speech and Hearing Research ·(unknown), (unknown), James C. Shanks	6
17	Effect of Prolonged Nasotracheal Intubation on Communication 1972 ·Journal of Speech and Hearing Disorders ·(unknown), James C. Shanks, (unknown)	3
18	Myotonic Dystrophy Initially Manifested by Speech Disability 1968 ·Journal of Speech and Hearing Disorders ·Bernd Weinberg, James F. Bosma, James C. Shanks, William DeMyer	10
19	Advantages in the use of esophageal speech by a laryngectomee. 1967 ·The Laryngoscope ·James C. Shanks	5
20	GASTROSCOPY FOR THE OTOLARYNGOLOGIST 1953 ·Archives of Otolaryngology - Head and Neck Surgery ·James C. Shanks	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact